Intravenous Infusions (XGHA:IIL) Other Long-Term Liabilities: GHS0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XGHA:IIL Intravenous Infusions Ltd XGHA:IIL
3 GF Score
Price GHS0.46
View Full Analysis

What is Intravenous Infusions Other Long-Term Liabilities?

Intravenous Infusions XGHA:IIL +6.98% 3 Other Long-Term Liabilities is GHS0.00 Mil as of . 20. GuruFocus rates XGHA:IIL with a GF Score™ of 3/100.

Intravenous Infusions's other long-term liabilities for the quarter that ended in . 20 was GHS0.00 Mil.

Intravenous Infusions Other Long-Term Liabilities Related Terms

Intravenous Infusions Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Other Long-Term Liabilities Chart

Intravenous Infusions Annual Data
Trend
Other Long-Term Liabilities

Intravenous Infusions Semi-Annual Data
Other Long-Term Liabilities
XGHA:IIL
3GF Score
Intravenous Infusions Ltd XGHA:IIL
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intravenous Infusions Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of GHS0.00 Mil mean?
Intravenous Infusions (XGHA:IIL) has a Other Long-Term Liabilities of GHS0.00 Mil as of . 20. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Intravenous Infusions and its competitors.
Is Intravenous Infusions' Other Long-Term Liabilities too high?
Intravenous Infusions' current Other Long-Term Liabilities is GHS0.00 Mil. Overall, Intravenous Infusions has a GF Score™ of 3/100, reflecting its overall financial health beyond just this single metric.
How does Intravenous Infusions' Other Long-Term Liabilities compare to PTLF and PCYN?
Intravenous Infusions' Other Long-Term Liabilities of GHS0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Intravenous Infusions and its competitors. Intravenous Infusions's current Other Long-Term Liabilities is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Other Long-Term Liabilities of GHS0.00 Mil. The current Other Long-Term Liabilities is GHS0.00 Mil. Intravenous Infusions' overall GF Score™ is 3/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Other Long-Term Liabilities is GHS0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.
3GF Score

Get the complete analysis for XGHA:IIL

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

GHS0.46
Price